In a finding that may cause a dramatic shift in the way scientists and researchers search for a therapy for Alzheimer's disease, a team of researchers led by Jeff Johnson, an associate professor at the School of Pharmacy, has discovered that increased expression of a protein called transthyretin in the brain appears to halt the progression of the disease. The findings appear in the current issue of The Journal of Neuroscience. ''This work shows convincingly that if we can intervene in Alzheimer's pathology by introducing molecules and drugs into the brain and increase transthyretin levels, we could slow the progression of the pathology.''